Viridian Therapeutics Inc
VRDN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.13B
Close$
$-10.25
135.3% downside
Current Fair Value
135.3% downsideOvervalued by 135.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.13 Billion |
|---|---|
| Enterprise Value | $3.21 Billion |
| Earnings per Share | $-3.32 |
| Beta | 0.96 |
| Outstanding Shares | 107,884,104 |
Return
| Return on Equity | -58.45% |
|---|---|
| Return on Assets | -35.27% |
| Return on Invested Capital | -37.63% |
Valuation & Multiples
| P/E Ratio | -6.99 |
|---|---|
| PEG | -26.68 |
| Price to Sales | - |
| Price to Book Ratio | 4.84 |
| Enterprise Value to Revenue | 45.16 |
| Enterprise Value to EBIT | -8.26 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-1.02
Consensus analyst estimateRevenue Estimate
$4.72 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$-0.94
Consensus analyst estimateRevenue Estimate
$36.59 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 21.55% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.53%▼ 126.33% |
|---|---|
| Total Invested | $11.70M▼ 99.53% |
| Investors Holding | 31▼ 196.00% |
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...